Prost A, Boiteau H L, Rossel-Renac F, Audran M, Caumon J P
Rev Rhum Mal Osteoartic. 1980 Nov;47(11):635-43.
Following several series of tests, it was shown that the administration of 500 mg/day of niflumic acid, at a dose of 250 mg morning and evening, causes in subjects with a weight between 65 and 75 kilos a moderate but permanent and relatively stable rise in the levels of plasma ionised fluorine. This constant concentration of ionised fluorine in the plasma contrasted with the marked and rapid variations which follow the ingestion of sodium fluoride, which is usually prescribed in the treatment of osteoporosis. This may explain why the fluoride ion is more active on osteogenesis when it is liberated in the organism from niflumic acid by way of metabolic processes. The dosage of 500 mg daily is much less than that which produces fluorosis after prolonged treatment; it suggests a trial of niflumic acid in the treatment of osteoporosis, respecting naturally the contra-indications, and supervising the digestive tract as always with anti-inflammatory drugs.
经过一系列测试表明，对于体重在65至75公斤之间的受试者，每天服用500毫克尼氟酸（早晚各250毫克）会导致血浆中离子化氟水平适度但持续且相对稳定地升高。血浆中这种恒定的离子化氟浓度与摄入通常用于治疗骨质疏松症的氟化钠后所出现的明显且快速的变化形成对比。这或许可以解释为何当氟离子通过代谢过程在体内从尼氟酸中释放出来时，它在骨生成方面更为活跃。每日500毫克的剂量远低于长期治疗后会导致氟中毒的剂量；这表明在治疗骨质疏松症时可以尝试使用尼氟酸，但当然要遵循禁忌症，并一如既往地对消化道进行监测，如同使用抗炎药物时那样。
